IL2 and peripheral neuropathy: In our previous study [13], we reported that phytohemagglutinin (PHA)-induced interleukin-2 (IL2) mRNA levels in ex vivo whole blood obtained prior to bortezomib treatment could predict the incidence of bortezomib-induced peripheral neuropathy.